Baidu
map

Lancet Infect Dis:埃博拉之下,疟疾防控不容乐观!

2015-04-27 MedSci MedSci原创

 埃博拉病毒在西非地区的持续性传播主要在圭亚那、利比里亚和塞拉利昂三国。埃博拉病毒感染者的高死亡率和高传染性已经使得这些国家的医疗卫生系统处于极其紧张的状态。因此,很少的病人可以使用医疗卫生设施,因为这些设施被关闭了。即使在正常开放的医院、诊所中,因为畏惧埃博拉病毒,门诊病人数也降低至10%。结果是,这些埃博拉疫情地区的疟疾防控近乎停滞,这直接导致了疟疾疫情的爆发和死亡率的上升。疟疾的流

埃博拉病毒在西非地区的持续性传播主要在圭亚那、利比里亚和塞拉利昂三国。埃博拉病毒感染者的高死亡率和高传染性已经使得这些国家的医疗卫生系统处于极其紧张的状态。因此,很少的病人可以使用医疗卫生设施,因为这些设施被关闭了。即使在正常开放的医院、诊所中,因为畏惧埃博拉病毒,门诊病人数也降低至10%。结果是,这些埃博拉疫情地区的疟疾防控近乎停滞,这直接导致了疟疾疫情的爆发和死亡率的上升。疟疾的流行将增加发热病人数,进一步地导致埃博拉病毒患者的确诊和治疗变得更为复杂。因此,有必要对爆发埃博拉病毒疫情的国家和地区的疟疾发病率和死亡率进行科学的评估。

研究人员从三个国家的人口学和卫生研究数据和埃博拉爆发前的疟疾干预覆盖率中估计疟疾的病例数和死亡数。随后,研究人员又估计了由于医疗卫生容量减少和潜在的臭虫杀虫剂递送的破坏导致的额外的病例数和死亡数。如果疟疾治疗由于埃博拉疫情而中断,那么三个国家的未经治疗的疟疾患者数将分别上升45%(圭亚那)、88%(塞拉利昂)和140%(利比里亚)。这相当于增加了350万疟疾患者,并将导致10900例疟疾病例死亡。大量的药物使用和杀虫剂的分配将大大减少埃博拉病毒对疟疾疫情的影响。

此项研究表明,由于医疗卫生系统容量降低,疟疾传播情况不容乐观,这将持续性地导致更多的死亡人数。大量的药物使用是一条有效的途径来减少死亡数。



原始出处:
Patrick G T Walker et al.Malaria morbidity and mortality in Ebola-affected countries caused by decreased health-care capacity, and the potential effect of mitigation strategies: a modelling analysis.Lancet Infect Dis 2015 Published Online April 24, 2015http://dx.doi.org/10.1016/S1473-3099(15)70124-6

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828077, encodeId=e4e818280e758, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 04 14:10:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648769, encodeId=c85b1648e6913, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Oct 07 21:10:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011976, encodeId=9a0520119e646, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 04 20:10:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22166, encodeId=744e22166be, content=地域特点, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Tue Apr 28 10:44:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22135, encodeId=79342213587, content=非洲人民太原生态了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=58.33.136.**, createdTime=Mon Apr 27 23:43:00 CST 2015, time=2015-04-27, status=1, ipAttribution=)]
    2015-07-04 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828077, encodeId=e4e818280e758, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 04 14:10:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648769, encodeId=c85b1648e6913, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Oct 07 21:10:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011976, encodeId=9a0520119e646, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 04 20:10:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22166, encodeId=744e22166be, content=地域特点, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Tue Apr 28 10:44:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22135, encodeId=79342213587, content=非洲人民太原生态了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=58.33.136.**, createdTime=Mon Apr 27 23:43:00 CST 2015, time=2015-04-27, status=1, ipAttribution=)]
    2015-10-07 yaanren
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828077, encodeId=e4e818280e758, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 04 14:10:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648769, encodeId=c85b1648e6913, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Oct 07 21:10:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011976, encodeId=9a0520119e646, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 04 20:10:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22166, encodeId=744e22166be, content=地域特点, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Tue Apr 28 10:44:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22135, encodeId=79342213587, content=非洲人民太原生态了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=58.33.136.**, createdTime=Mon Apr 27 23:43:00 CST 2015, time=2015-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1828077, encodeId=e4e818280e758, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 04 14:10:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648769, encodeId=c85b1648e6913, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Oct 07 21:10:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011976, encodeId=9a0520119e646, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 04 20:10:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22166, encodeId=744e22166be, content=地域特点, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Tue Apr 28 10:44:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22135, encodeId=79342213587, content=非洲人民太原生态了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=58.33.136.**, createdTime=Mon Apr 27 23:43:00 CST 2015, time=2015-04-27, status=1, ipAttribution=)]
    2015-04-28 lovejing

    地域特点

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1828077, encodeId=e4e818280e758, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Jul 04 14:10:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648769, encodeId=c85b1648e6913, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Wed Oct 07 21:10:00 CST 2015, time=2015-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011976, encodeId=9a0520119e646, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 04 20:10:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22166, encodeId=744e22166be, content=地域特点, beContent=null, objectType=article, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Tue Apr 28 10:44:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22135, encodeId=79342213587, content=非洲人民太原生态了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=58.33.136.**, createdTime=Mon Apr 27 23:43:00 CST 2015, time=2015-04-27, status=1, ipAttribution=)]
    2015-04-27 58.33.136.**

    非洲人民太原生态了

    0

相关资讯

Vaccine:预防啮齿类动物的埃博拉病毒长效疫苗问世

近日,来自英国普利茅斯大学的研究人员在国际学术期刊Vaccine发文宣称他们开发出针对埃博拉病毒的长效疫苗,应用该疫苗或可降低野生非洲猿的埃博拉病毒感染,对非洲埃博拉病毒的预防治疗具有重要意义。   非洲猿是埃博拉病毒向人类传播的一个主要传染源。因此预防非洲猿发生埃博拉病毒感染能够降低埃博拉病毒在非洲人口中爆发的可能性。埃博拉病毒感染对非洲猿同样具有致死性,同时也是威胁这些野

埃博拉抗体药物将量产?

据日本《读卖新闻》3月2日报道,日本田边三菱制药公司公布称,将会与美国政府携手研究埃博拉出血热病毒抗体。据悉,埃博拉对抗措施是美国国家级项目,而美国政府也将负担费用,进行量产药物的有关技术开发研究。 美国研究人员正在开发中的新药“ZMapp”虽还未认证,但却是埃博拉出血热治疗药物的有力候补之一。而田边三菱制药的子公司“Medicago”则会就如何量产药物中所含抗体进行研究。“Medicago

默克&NewLink 埃博拉疫苗启动四期临床试验

世卫组织WHO 5日宣布默克 -NewLink 共同研发的埃博拉疫苗将于3月7日在几内亚开始四期临床试验。 尽管西非的埃博拉疫情有所控制,但全球健康组织的权威WHO依然相当重视埃博拉病毒相关药物的研发,继默克埃博拉疫苗之后,GSK的疫苗也即将进行四期临床试验。“一定要确保疫苗供应充足。”WHO官员说道。 据统计,自2013年12月埃博拉疫情大爆发以来,已经有23,900名确诊或疑似病例,其

Nature:siRNA干预治疗埃博拉病毒感染新进展

埃博拉病毒在西非地区的流行仍未得到有效控制,其造成的病例和死亡比之前的病毒爆发流行都要严重,是一次前所未有的大灾难。近日,著名国际学术期刊nature在线发表了美国科学家关于埃博拉病毒治疗进展的相关研究。   在此研究之前,科学家们已经研发出一些病毒接触后干预手段,对返回欧洲和美国的病人进行治疗。但这些治疗手段对于治疗埃博拉病毒新暴发亚型的体内疗效仍未可知。   在该项

一个赴非抗埃医生生前发给女儿的微信

一个家庭的群由于爸爸在非洲,妈妈在四川,女儿在上海,为了交流方便,女儿专门建了一个家庭微信群他第一次点赞“爸爸,等你平安归来,女儿带你去海钓,好不好?”刚学会用微信的爸爸在下面调皮地点了个赞我们为他点赞今年1月,爸爸在执行援外医疗任务时突发大面积心肌梗塞,经全力抢救无效,不幸逝世,年仅50岁2014年2月以来,西非地区爆发了大规模的埃博拉出血热疫情,中国政府和军队第一时间向西非各国派遣医疗专家

Lancet:中国江苏泰州新型埃博拉疫苗安全性和免疫原性的研究

背景 到现在为止,所有测试的埃博拉病毒疫苗都是根据1976年病扎伊尔爆发的毒株,我们的目的是评估一个新的重组腺病毒5型的基于矢量的埃博拉疫苗的2014年流行的糖蛋白菌株安全性和免疫原性表达。 方法我们在中国江苏省泰州县的一个站点做的随机,双盲,安慰剂对照,第一阶段的临床试验。健康成人(年龄18-60岁)依次登记和随机分配(2:1),由计算机生成的随机化块(6的块大小),接受安慰剂,低剂量的腺病毒

Baidu
map
Baidu
map
Baidu
map